초록 ▼

The splicing variant D of the TAK1 gene is activated by short double-stranded RNAs in a sequence specific manner. Activation of TAK1-D leads to the downstream activation of the p38 MAPK and of SAPK/JNK but not the NFκB pathway. The current invention therefore provides a method of inducing apoptosis

The splicing variant D of the TAK1 gene is activated by short double-stranded RNAs in a sequence specific manner. Activation of TAK1-D leads to the downstream activation of the p38 MAPK and of SAPK/JNK but not the NFκB pathway. The current invention therefore provides a method of inducing apoptosis and/or cell cycle arrest in a cancer cell comprising contacting said cell with an agonist of Tak1-D function. The invention further provides a method of modulating inflammation and the treatment of cancer by the administration of an agonist of Tak1-D function or expression. In yet another aspect, the invention provides a method of inducing p38 MAPK and SAPK/JNK signaling in a cell comprising contacting said cell with an agonist of Tak1-D function or expression.

대표청구항 ▼

1. A method of inducing apoptosis and/or cell cycle arrest in a lung cancer cell that expresses Tak1-D comprising contacting said cell with a double-stranded (ds) RNA directed to an mRNA for TLK1, wherein said dsRNA has the sequence NC(A/U)(A/U)(A/U)(A/U)GAX4-6AUGAN, wherein in N is any base or null

1. A method of inducing apoptosis and/or cell cycle arrest in a lung cancer cell that expresses Tak1-D comprising contacting said cell with a double-stranded (ds) RNA directed to an mRNA for TLK1, wherein said dsRNA has the sequence NC(A/U)(A/U)(A/U)(A/U)GAX4-6AUGAN, wherein in N is any base or null and X is any base, GGCUUUUGACCUUUAUGAA (SEQ ID NO: 1), CCAAAAGAAGAUGUGAUGA (SEQ ID NO:6), 5′-GGCUUUUGACCUUUAUGAAU-U (SEQ ID NO:7) or 3′-CCGAAAACUGGAAAUACUUA-A (SEQ ID NO:8). 2. The method of claim 1, wherein said dsRNA is encapsulated in a lipid vehicle. 3. The method of claim 1, wherein said cancer cell is a metastatic cancer cell, a recurrent cancer cell, a multi-drug resistant cancer cell. 4. The method of claim 1, further comprising contacting said cell with a second apoptosis-inducing agent. 5. The method of claim 4, wherein said second apoptosis-inducing agent is a chemotherapeutic, radiation, or a polypeptide inducer of apoptosis. 6. A method of treating a subject with lung cancer, cells of which express Tak 1-D, comprising administering to said subject a double-stranded (ds) RNA directed to an mRNA for TLK1, wherein said dsRNA has the sequence NC(A/U)(A/U)(A/U)(A/U)GAX4-6AUGAN, wherein in N is any base or null and X is any base, GGCUUUUGACCUUUAUGAA (SEQ ID NO: 1), CCAAAAGAAGAUGUGAUGA (SEQ ID NO:6), or 5′-GGCUUUUGACCUUUAUGAAU-U (SEQ ID NO:7) or 3′-CCGAAAACUGGAAAUACUUA-A (SEQ ID NO:8). 7. The method of claim 6, wherein said dsRNA is encapsulated in a lipid vehicle. 8. The method of claim 6, wherein said cancer is metastatic cancer, recurrent cancer, or a multi-drug resistant cancer cell. 9. The method of claim 6, further comprising contacting said cell with a second apoptosis-inducing agent. 10. The method of claim 9, wherein said second apoptosis-inducing agent is a chemotherapeutic, radiation, or a polypeptide inducer of apoptosis. 11. The method of claim 6, wherein said dsRNA is administered intratumorally, into tumor vasculature, loco-regional to a tumor, or systemically.